InspireMD (NYSE:NSPR) Shares Up 0% – Here’s What Happened

Posted by Geri Gentry on Aug 6th, 2026

Shares of InspireMD, Inc. (NYSE:NSPR – Get Free Report) were up 0% on Wednesday . The stock traded as high as $0.7231 and last traded at $0.72. 39,792 shares were traded during trading, a decline of 75% from the average daily volume of 156,890 shares. The stock had previously closed at $0.7199.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Piper Sandler reiterated an “overweight” rating and issued a $3.00 price target (down from $4.00) on shares of InspireMD in a research note on Tuesday, May 5th. Lake Street Capital set a $4.00 price target on InspireMD in a report on Monday, May 4th. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $4.50.

Check Out Our Latest Stock Analysis on NSPR

InspireMD Trading Up 0.0%

The stock has a market capitalization of $33.72 million, a price-to-earnings ratio of -0.96 and a beta of 0.78. The firm has a 50-day moving average of $0.74 and a 200-day moving average of $1.23.

Insider Activity

In other news, Director Paul Stuka acquired 65,626 shares of the business’s stock in a transaction dated Friday, May 8th. The shares were acquired at an average cost of $1.16 per share, with a total value of $76,126.16. Following the completion of the acquisition, the director owned 622,871 shares of the company’s stock, valued at approximately $722,530.36. This trade represents a 11.78% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marvin Slosman acquired 21,000 shares of the business’s stock in a transaction dated Tuesday, May 12th. The stock was purchased at an average cost of $1.20 per share, for a total transaction of $25,200.00. Following the completion of the acquisition, the chief executive officer directly owned 3,556,658 shares of the company’s stock, valued at approximately $4,267,989.60. This trade represents a 0.59% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have acquired 116,626 shares of company stock worth $130,826. Company insiders own 34.06% of the company’s stock.

Hedge Funds Weigh In On InspireMD

Hedge funds and other institutional investors have recently bought and sold shares of the business. Raymond James Financial Inc. raised its position in InspireMD by 28.9% during the 2nd quarter. Raymond James Financial Inc. now owns 44,604 shares of the company’s stock worth $101,000 after buying an additional 10,000 shares during the last quarter. Citadel Advisors LLC lifted its stake in InspireMD by 45.0% during the 3rd quarter. Citadel Advisors LLC now owns 37,954 shares of the company’s stock valued at $91,000 after acquiring an additional 11,778 shares during the period. Rosalind Advisors Inc. boosted its holdings in shares of InspireMD by 0.6% in the 2nd quarter. Rosalind Advisors Inc. now owns 2,289,099 shares of the company’s stock valued at $5,196,000 after acquiring an additional 14,109 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of InspireMD in the 4th quarter valued at $30,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of InspireMD in the first quarter worth $29,000. Institutional investors and hedge funds own 44.78% of the company’s stock.

About InspireMD

(Get Free Report)

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.